11 institutions hold shares in Can-Fite BioPharma Ltd. (CANF), with 183.12k shares held by insiders accounting for 1.19% while institutional investors hold 6.60% of the company’s shares. The shares outstanding are 15.41M, and float is at 14.76M with Short Float at 2.33%. Institutions hold 6.52% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Renaissance Technologies, LLC with over 0.12 million shares valued at $0.21 million. The investor’s holdings represent 0.77% of the CANF Shares outstanding. As of Dec 30, 2020, the second largest holder is Morgan Stanley with 17676.0 shares valued at $31463.0 to account for 0.11% of the shares outstanding. The other top investors are Susquehanna Fundamental Investments, LLC which holds 17300.0 shares representing 0.11% and valued at over $30794.0, while Susquehanna International Group, LLP holds 0.10% of the shares totaling 15323.0 with a market value of $27274.0.
Can-Fite BioPharma Ltd. (AMEX: CANF) is 42.13% higher on its value in year-to-date trading and has touched a low of $1.10 and a high of $2.95 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CANF stock was last observed hovering at around $2.35 in the last trading session, with the day’s gains setting it 0.18% off its average median price target of $5.00 for the next 12 months. It is also 49.4% off the consensus price target high of $5.00 offered by 1 analysts, but current levels are 49.4% higher than the price target low of $5.00 for the same period.
Currently trading at $2.53, the stock is 12.92% and 25.20% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 13.67 million and changing 7.66% at the moment leaves the stock 28.24% off its SMA200. CANF registered 68.67% gain for a year compared to 6-month loss of 8.58%. The firm has a 50-day simple moving average (SMA 50) of $2.1036 and a 200-day simple moving average (SMA200) of $1.9504.
The stock witnessed a 27.78% gain in the last 1 month and extending the period to 3 months gives it a 45.40%, and is -6.30% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.11% over the week and 10.38% over the month.
Can-Fite BioPharma Ltd. (CANF) has around 8 employees, a market worth around $39.00M and $0.81M in sales. Distance from 52-week low is 130.00% and -14.24% from its 52-week high.
Can-Fite BioPharma Ltd. (CANF) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Can-Fite BioPharma Ltd. (CANF) is a “Buy”. 1 analysts offering their recommendations for the stock have an average rating of 2.00, where 0 rate it as a Hold and 0 think it is a “Overweight”. 1 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Can-Fite BioPharma Ltd. is expected to release its quarterly report on 06/03/2021 and quarterly earnings per share for the current quarter are estimated at -$0.19 with sales reaching $360k over the same period.The EPS is expected to grow by 56.70% this year, but quarterly earnings will post -50.30% year-over-year. Quarterly sales are estimated to shrink -68.80% in year-over-year returns.